摘要
肝纤维化(hepatic fibrosis,HF)是多由于各种损肝因素所致的肝内纤维组织异常增生与沉积的病理过程。现已有研究表明转化生长因子β1(Transforming Growth Factorβ1,TGF-β1)是促肝纤维化的重要因子之一,TGF-β1/Smad信号通路是HF主要的信号转导通路,因此采取各种的措施阻断该信号成为抗纤维化的重要治疗靶点。中药在治疗肝纤维化具有多途径、多环节、多靶点的优势,近年来越来越多学者以中药治疗肝纤维化集中在阻断或转导TGF-β1/Smad信号通路上,文章基于TGF-β1/Smad信号通路抗肝纤维化的中药研究概况做一综述,揭示现代中医药作用的靶点和调控机理,为HF的防治及中医药现代研究提供新的思路和策略。
Hepatic fibrosis(HF)is a pathological process of abnormal proliferation and deposition of intrahepatic fibrous tissue due to various liver damage factors.Studies have shown that transforming growth factorβ1(TGF-β1)is one of the important factors promoting liver fibrosis.The TGF-β1/Smad signaling pathway is the main signal transduction pathway of HF,and so using various methods to block this signal is as an important therapeutic target for anti-fibrosis.Traditional Chinese medicine has the advantages of multiple pathways,multiple links and multiple targets in the treatment of liver fibrosis.In recent years,more and more scholars have used traditional Chinese medicine to treat liver fibrosis in blocking or transducing TGF-β1/Smad signaling pathway.A review of the research on TGF-β1/Smad signaling pathway for anti-fibrosis Chinese medicine revealed the target and regulation mechanism of modern Chinese medicine,and provided new ideas and strategies for the prevention and treatment of HF and modern research of traditional Chinese medicine.
作者
陈美岑
王振常
吕黄华
聂琨梅
李小藩
CHEN Meicen;WANG Zhenchang;LYU Huanghua;NEI Kunmei;LI Xiaofan(Guangxi University of Traditional Chinese Medicine,Nanning 530001,Guangxi,China;International Zhuang Medical Hospital Affiliated to Guangxi University of Traditional Chinese Medicine,Nanning 530001,Guangxi,China)
出处
《辽宁中医杂志》
CAS
2020年第5期207-210,共4页
Liaoning Journal of Traditional Chinese Medicine
基金
国家自然科学基金(81660745)
